Investor Presentaiton
Segment (Healthcare)
Chromatography: Demand is expanded for diabetes treatments applications in Europe, the United
States, and Asian markets
APIs and their intermediates : Sales of nucleic acid drug substances, anti-ulcer drug intermediates,
and insomnia treatment drug intermediates expanded
Expansion plans: Completion of new silica gel production facility by 2024 at Matsuyama Plant,
Promoting expansion plans for completion of new silica gel production facility and expansion by
2026 at Amagasaki Plant
Net sales
-Operating income
(Millions of yen)
Variance (Operating income, YoY)
5,273
5,372
2,661
2,307
1H FY2022 X
1H FY2023
Net sales (up ¥0.1 billion YoY)
Chromatography*
APIs and Their Intermediates
+0.1
+0
2.3
1H
FY2022 *
* Pharmaceutical purification materials(Silica gel), analytical equipment, packed columns
*Figures by segment for FY2022 are approximate figures reclassified into new segments
Something Better with Chemicals
Sales
unit
Feedstock
price
costs
+0.2
(0.1)
Production
and sales
volume
+0.5
(Billions of yen)
Fixed costs
(0.3)
2.6
1H
FY2023
OSAKA SODA
7View entire presentation